- Home
- » Tags
- » Elacestrant
Top View
- Clinical Update
- Drug Repurposing Compound Library Plus (96-Well)
- G1T48, an Oral Selective Estrogen Receptor Degrader, and the CDK4/6 Inhibitor Lerociclib Inhibit Tumor Growth in Animal Models of Endocrine‑Resistant Breast Cancer
- SABCS 2017 WEBCAST Elacestrant (RAD1901) Update December 7, 2017
- Continues to Show Promise in Advanced ER+ / HER2- Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
- The Emerging Role of ESR1 Mutations in Luminal Breast Cancer As a Prognostic and Predictive Biomarker of Response to Endocrine Therapy
- Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, a Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post‑Menopausal Women
- Oral Selective Estrogen Receptor Degraders (Serds) As a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
- A Phase 1B Study Evaluating the Effect of Elacestrant Treatment on Estrogen
- SERD), Has Antitumor Activity in Multiple Erþ Breast Cancer Patient-Derived Xenograft Models Teeru Bihani, Hitisha K
- Hitisha Patel, Julie Tao, Heike Arlt, and Teeru Bihani P4-13-03
- INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri